Capricor Therapeutics: A High Risk/High Reward Name

2026-01-10 04:12:54 ET

Shares of Duchenne muscular dystrophy concern Capricor Therapeutics, Inc. ( CAPR ) more than tripled on December 3, 2025 after releasing seemingly approvable Phase 3 disease progression data. The HOPE-3 results, including a 54% slowing of upper limb performance deterioration versus placebo (p=0.029) at 12 months, should help deramiocel overcome a July 2025 CRL from the FDA. With an opportunity estimated between $7 billion and $27 billion by 2030 and commercial partnerships in place for the U.S. and Japan, the rise in Capricor’s market cap merited a deeper dive. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: